Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands.

Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily. J Biol Chem (2015) 1.00

Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol (2014) 0.86

The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterol Motil (2015) 0.81

GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Br J Pharmacol (2015) 0.79

The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front Pharmacol (2015) 0.78

Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones. Bioorg Med Chem Lett (2016) 0.75

Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor. Biochemistry (2017) 0.75

Current approaches for the discovery of drugs that deter substance and drug abuse. Expert Opin Drug Discov (2014) 0.75

The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress. Mol Brain (2017) 0.75

Crystal structure of rhodopsin: A G protein-coupled receptor. Science (2000) 28.60

High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32

Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature (2011) 13.92

Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30

Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol (2004) 6.80

Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (1996) 6.50

Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature (2011) 5.35

Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci U S A (2002) 4.12

The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature (2011) 3.79

Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem (2001) 3.49

Site of G protein binding to rhodopsin mapped with synthetic peptides from the alpha subunit. Science (1988) 2.66

Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A (2001) 2.58

Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation. Nat Struct Mol Biol (2009) 2.32

Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure (2012) 2.08

Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91

N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci (2010) 1.78

Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry (1996) 1.66

The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63

Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60

A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem (2010) 1.59

The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain (2008) 1.54

Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem (2000) 1.49

An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem (2003) 1.43

Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem (1997) 1.42

Molecular characterization of a purified 5-HT4 receptor: a structural basis for drug efficacy. J Biol Chem (2005) 1.41

GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol (2010) 1.39

The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene (2010) 1.36

The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene (2010) 1.32

Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem (2004) 1.26

Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther (2010) 1.24

FRET-based monitoring of conformational change of the beta2 adrenergic receptor in living cells. Biochem Biophys Res Commun (2006) 1.23

Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization. Mol Pharmacol (2009) 1.23

A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol (2010) 1.21

Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol (2011) 1.17

Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem (2011) 1.11

Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem (2010) 1.10

The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol (2012) 1.06

Visualization of dynamic trafficking of a protein kinase C betaII/green fluorescent protein conjugate reveals differences in G protein-coupled receptor activation and desensitization. J Biol Chem (1998) 1.05

Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther (2011) 1.03

The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene (2012) 1.00

Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2011) 1.00

A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther (2013) 0.93

Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor. J Biol Chem (2012) 0.89

Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J Med Chem (2013) 0.88

Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. ACS Med Chem Lett (2012) 0.86

Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1. Drug Dev Res (2010) 0.85

The universal bed model for patient care improves outcome and lowers cost in cardiac surgery. J Thorac Cardiovasc Surg (2011) 0.81

An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 5.60

Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron (2005) 4.78

Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci (2003) 4.50

Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci (2004) 4.44

Functional genomic screen for modulators of ciliogenesis and cilium length. Nature (2010) 3.63

Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60

Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science (2003) 3.52

Food reward in the absence of taste receptor signaling. Neuron (2008) 3.37

Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron (2004) 2.76

Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol (2002) 2.76

A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 2.76

Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science (2004) 2.64

Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A (2003) 2.62

Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol (2009) 2.60

Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes (2007) 2.59

Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol (2002) 2.54

The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem (2002) 2.47

Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41

Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A (2008) 2.23

The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci (2007) 2.22

Activity-dependent internalization of smoothened mediated by beta-arrestin 2 and GRK2. Science (2004) 2.19

Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron (2006) 2.19

Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron (2003) 2.03

Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci (2002) 2.01

MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A (2009) 2.00

Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron (2006) 1.98

Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98

Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci (2007) 1.93

Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem (2005) 1.93

Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science (2009) 1.88

Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol (2010) 1.86

Pregnenolone can protect the brain from cannabis intoxication. Science (2014) 1.85

Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85

Elimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission. PLoS Biol (2011) 1.84

N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology (2007) 1.83

Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant. Proc Natl Acad Sci U S A (2004) 1.78

Dopaminergic control of sleep-wake states. J Neurosci (2006) 1.77

Persistent oxidative stress due to absence of uncoupling protein 2 associated with impaired pancreatic beta-cell function. Endocrinology (2009) 1.71

Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem (2002) 1.67

Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60

A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem (2010) 1.59

The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry (2009) 1.58

TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A (2011) 1.55

Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc Natl Acad Sci U S A (2008) 1.52

Aberrant responses in social interaction of dopamine transporter knockout mice. Behav Brain Res (2004) 1.52

Rhodium(I)-catalyzed [2+2+1] cycloadditions of 1,3-dienes, alkenes, and CO. J Am Chem Soc (2004) 1.51

Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol (2002) 1.51

Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci (2003) 1.49

Beta-arrestin 2 regulates zebrafish development through the hedgehog signaling pathway. Science (2004) 1.47

PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci (2009) 1.46

Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci (2007) 1.45

Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J Biol Chem (2003) 1.45

An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem (2003) 1.43

Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol (2002) 1.40

Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry (2012) 1.39

Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacology (2005) 1.39

CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res (2009) 1.38

A beta-arrestin binding determinant common to the second intracellular loops of rhodopsin family G protein-coupled receptors. J Biol Chem (2005) 1.38

Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2. Mol Cell Biol (2006) 1.38

Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation. J Biol Chem (2007) 1.34

RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem (2003) 1.32

Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion. J Biol Chem (2001) 1.32

Molecular mechanism of human Nrf2 activation and degradation: role of sequential phosphorylation by protein kinase CK2. Free Radic Biol Med (2007) 1.31

Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol (2005) 1.31

beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. J Biol Chem (2002) 1.30

Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J Neurosci (2012) 1.29

Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J Immunol (2003) 1.29

N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol (2002) 1.28

Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A (2003) 1.27

The vesicular acetylcholine transporter is required for neuromuscular development and function. Mol Cell Biol (2009) 1.27

CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol (2012) 1.26

Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem (2004) 1.26

Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J Neurosci (2004) 1.26